Autonomix Medical, Inc. (AMIX)
Market Cap | 4.05M |
Revenue (ttm) | n/a |
Net Income (ttm) | -13.63M |
Shares Out | 2.46M |
EPS (ttm) | -12.86 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 8,877 |
Open | 1.690 |
Previous Close | 1.670 |
Day's Range | 1.620 - 1.690 |
52-Week Range | 1.520 - 75.800 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 30, 2025 |
About AMIX
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. It has an agreement with NoiseFi... [Read more]
Financial Performance
Financial StatementsNews

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)
THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted trea...

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
THE WOODLANDS, TX, March 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to re...

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company's Proprietary Catheter-Based Technology
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications Proprietary sensing and ablation technology has demonstrated potential to more pre...

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation
Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF”) Generator

Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting
Presentation to highlight Autonomix's catheter-based technology and key findings from lead-in patients in ongoing human clinical trial in pancreatic cancer pain patients

Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer with topline data on track for 1H 2025

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
THE WOODLANDS, TX, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to rev...

Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025
Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing Manufacturing of ASIC microchip for targeted use in humans has been initiated Company ad...

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
Live video webcast on Wednesday, January 22 nd at 4:00 PM ET THE WOODLANDS, TX, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical devic...

Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting
THE WOODLANDS, TX, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to rev...

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company's Proprietary Catheter-Based Technology
Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed preclinical study evaluating targeted nerve ablation demonstrate...

Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025
First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the source

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option
THE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treat...

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treat...

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 week...

Autonomix Medical, Inc.'s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial
Access the Virtual Investor “What This Means” Segment here

Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.

Why Is Nao-Cap Neurology Focused Autonomix Medical Stock Trading Higher On Monday?
Autonomix Medical, Inc. AMIX stock is trading higher on Monday, with a strong session volume of 6.11 million compared to the average volume of 22.87 thousand, as per data from Benzinga Pro.

Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th
THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treat...

Autonomix Announces Reverse Stock Split
THE WOODLANDS, TX, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treat...

Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
Live webcast fireside chat on Tuesday, October 15 th at 2:30 PM ET THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical...

Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum
THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted trea...

Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference
THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to rev...

Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company's ongoing proof-of-concept (PoC) human c...

Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source